Dr. Falzarano received his Ph.D. from the Department of Medical Microbiology at the University of Manitoba in 2010 for determining the functional importance of post-translation modifications of Ebola virus glycoproteins. He then completed a post-doc at Rocky Mountain Laboratories, part of the National Institute of Allergy and Infectious Disease, in Hamilton, MT where he investigated antiviral strategies for Ebola and Middle East respiratory syndrome coronavirus (MERS-CoV). This included the development of a new animal model and the first potential treatment for MERS-CoV. Dr. Falzarano joined VIDO-InterVac as a Research Scientist in 2014.
- Development of animal models and vaccines for emerging viruses
- Structure-based coronavirus vaccine design